Compare Novavax Inc (NVAX) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs VanEck Semiconductor ETF — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while VanEck Semiconductor ETF trades at $570.66. Which is the better fit depends on your goals.
| NVAX | SMH | |
|---|---|---|
Market Cap | $1.62B | — |
Sector | Health | — |
52-Week High | $11.19 | $668.91 |
52-Week Low | $6.22 | $300.83 |
Enterprise Value | $1.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
SMH trades at $573.73, up 1.19% with a bullish technical outlook supported by moving averages and positive momentum indicators. The semiconductor ETF benefits from strong AI infrastructure demand, with recent NVIDIA earnings and industry expansion driving investor interest. Institutional activity shows continued accumulation, including a $678,000 position by Greenland Capital Management.
Outlook remains positive given AI-driven semiconductor demand, though risks include potential tariff impacts and market volatility. The ETF's diversified exposure to chip leaders offers growth potential while mitigating single-stock risk, supported by Wall Street's constructive stance on the sector's long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
